Pharmacokinetic optimisation of the treatment of deep vein thrombosis

Clinical Pharmacokinetics

Volumn 32, Issue 2, 1997, Pages 145-172

  Iorio, Alfonso ^a   Agnelli, Giancarlo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; WARFARIN;

BLEEDING; BLOOD CLOTTING TEST; BODY WEIGHT; CLINICAL TRIAL; COMPUTER ANALYSIS; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG MONITORING; DRUG SENSITIVITY; HEIGHT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; METHODOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK; RISK BENEFIT ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0031055550     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199732020-00005     Document Type: Review

References (265)

1. Hirsh J, Fuster V. AHA Medical/Scientific Statement. Special Report. Guide to anticoagulant therapy. Pt 2: oral anticoagulants. Circulation 1994; 89: 1469-80
2. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; I: 1309-12
3. Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long term anticoagulant treatment in symptomatic calf vein thrombosis. Lancet 1985; II: 515-8
4. Hull RD, Delmore T, Genton E. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-9
5. Albrechtsson U, Anderson J, Einarsson E, et al. Streptokinase treatment of deep venous thrombosis and the post-thrombotic syndrome. Arch Surg 1981; 116: 33-7
6. Kakkar VV, Lawrence D. Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis: a prospective study. Am J Surg 1985; 150 (4A): 54-63
7. Barras JP, Widmer M, Zemp E, et al. Sequelles de la thrombose veineuse. J Mal Vasc 1991; 16: 115-8
8. Brandjes DPM, Heijboer H, Bùller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1485-9
9. Hirsh J, Fuster V. AHA Medical/Scientific Statement. Special Report. Guide to anticoagulant therapy. Pt 1: heparin. Circulation 1994; 89: 1449-68
10. Hull RD, Delmore T, Carter C. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94
11. Coon WW, Willis III PW. Recurrence of venous thromboembolism. Surgery 1973; 73: 823-7
12. O'Sullivan EF. Duration of anticoagulant therapy in venous thromboembolism. Med J Aust 1972; 2: 1104-7
13. Holmgren K, Andersson G, Fagrell B, et al. One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218: 279-84
14. Schulman A, Rhedin A-S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulation therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5
15. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11
16. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximalvein thrombosis. N Engl J Med 1990; 322: 1260-6
17. Gallus A, Jaekaman J, Tillet J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; II: 1293-6
18. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5
19. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74
20. Bentley PG, Kakkar VV, Scully MF. An objective study of alternative methods of heparin administration. Thromb Res 1980; 18: 177-87
21. Holm HA, Finnanger B, Hartmann A. Heparin treatment of deep venous thrombosis in 280 patients: symptoms related to dosage. Acta Med Scand 1984; 215: 47-53
22. Hull RD, Raskob GE, Hirsh J. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-14
23. Walker MG, Shaw JW, Thomson GJL. Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multi-centre prospective randomised trial. BMJ 1987; 294: 1189-92
24. Doyle DJ, Turpie AGG, Hirsh J. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med 1987; 107: 441-5
25. Hull RD, Raskob GE, Pineo GF. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82
26. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483-504
27. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429-53
28. Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980; 5: 204-20
29. Lindhal U, Backstrom G, Hook M, et al. Structure of the antithrombin binding site in heparin. Proc Natl Acad Sci USA 1979; 76: 3198-302
30. Loscalzo J, Vaughan DE. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987; 79: 1749-55
31. Bjork I, Lindhal U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982; 48: 161-82
32. Cipolle RJ, Seifert RD, Neilan BA, et al. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther 1981; 29: 387-93
33. Jick H. Efficacy and toxicity of heparin in relation to age and sex. N Engl J Med 1968; 279: 284-6
34. Tenero DM. Comparative dosage and toxicity of heparin sodium in the treatment of patients with pulmonary embolism versus deep-vein thrombosis. Clin Pharm 1989; 8: 40-3
35. Cipolle RJ, Rodvold KA. Heparin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic monitoring. 3rd ed. Vancouver (WA): Applied Therapeutics, Inc., 1992: 1-39
36. Bjornsson TD, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther 1982; 31: 104-13
37. Boneu B, Dol F, Caranobe C, et al. Pharmacokinetics of heparin and related polysaccharides. Ann NY Acad Sci 1989; 556: 282-91
38. de Swart CAM, Nijmeyer B, Roelofs JMM, et al. Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60: 1251-8
39. McAvoy TJ. Pharmacokinetic modeling of heparin and its clinical implication. J Pharmacokinet Biopharm 1979; 7: 331-54
40. Estes JW. The kinetics of heparin. Ann NY Acad Sci 1971; 179: 187-204
41. McDonald MM. Heparin clearance in the newborn. Pediatr Res 1981; 15: 1015-8
42. McDonald MM, Hathaway WE. Anticoagulant therapy by continuous heparinisation in newborn and older infants. J Pediatr 1982; 101: 451-7
43. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992; 22: 359-74
44. Beermann B, Lahnborg G. Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine. Thromb Haemost 1981; 45: 24-6
45. Talstad I. Heparin therapy adjusted for body weight. Am J Clin Pathol 1985; 83: 378-81
46. Ellison MJ. Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 1989; 8: 65-8
47. Gunnarsson PS, Sawyer WT, Montague D, et al. Appropriate use of heparin?: empiric versus nomogram-based dosing. Arch Intern Med 1995; 155: 526-32
48. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a 'standard care' nomogram: a randomized controlled trial. Ann Intern Med 1993; 119: 874-81
49. Hirsh J, van Acken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53: 691-5
50. Simon TL, Hyers TM, Gaston JP, et al. Heparin pharmacokinetics: increased requirements in pulmonary embolism. Br J Haematol 1978; 11: 111-20
51. Kandrotas RJ, Gal P, Douglas JB, et al. Altered heparin pharmacodynamics in patients with pulmonary embolism. Ther Drug Monit 1992; 14: 360-5
52. Benchekroun S, Eychenne B, Mericq O, et al. Heparin half-life and sensitivity in normal subjects and in patients affected by deep vein thrombosis. Eur J Clin Invest 1986; 16: 536-9
53. Perry PJ. Heparin half-life in normal and impaired renal function. Clin Pharmacol Ther 1974; 16: 514-9
54. Teien AN, Bjoomson J. Heparin elimination in uraemic patients on hemo-dialysis. Scand J Haematol 1976; 17: 29-35
55. Sette H. Heparin response and clearance in acute and chronic liver disease. Thromb Haemost 1985; 54: 591-4
56. Bara L, Billaud E, Kher A, et al. Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin. Semin Thromb Hemost 1985; 11: 316-7
57. Bjornsson TD, Wolfman KM. Intersubject variability in the anticoagulant response to heparin in vitro. Eur J Clin Pharmacol 1982; 21: 491-7
58. Bjornsson TD, Wolfman KM. Determinants of the anticoagulant effect of heparin in vitro. Ann NY Acad Sci 1981; 370: 656-61
59. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-28
60. Pini M, Pattacini C, Quintavalla R. Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis: a randomized clinical trial. Thromb Haemost 1990; 64: 222-6
61. Hommes DW, Bura A, Mazzolai L. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: a meta-analysis. Ann Intern Med 1992; 116: 279-84
62. Jacques LB, Kavanagh LW. Protamine neutralization for heparin. Can J Pharmacol Sci 1977; 12: 44-7
63. Penner JA. Managing the hemorrhagic complications of heparin therapy. Hematol Oncol Clin North Am 1993; 7: 1281-9
64. Hubbard AR, Jennings CA. Neutralization of heparin sulphate and low molecular weight heparin by protamine. Thromb Haemost 1985; 53: 86-9
65. Powers PJ. Studies on the frequency of heparin-associated thrombocytopenia. Thromb Res 1984; 33: 439-43
66. Cipolle RJ. Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients. Ther Drug Monit 1985; 5: 205-11
67. Silver D. Heparin-induced thrombocytopenia, thrombosis, and hemorrhage. Ann Surg 1983; 198: 301-6
68. Ramirez-Lassepas M. Heparin-induced thrombocytopenia in patients with cerebrovascular ischemic disease. Neurology 1984; 34: 736-40
69. Elliott CG, Hiltunen SJ, Suchyta M, et al. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med 1994; 154: 999-1004
70. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152: 1589-95
71. Wheeler AP, Jaquiss RDB, Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med 1988; 148: 1321-5
72. Fennerty AG, Thomas P, Backhouse G, et al. Audit of control of heparin treatment. BMJ 1985; 290: 27-8
73. Saya FG, Coleman LT, Martinoff JT. Pharmacist directed heparin therapy using a standard dosing and monitoring protocol. Am J Hosp Pharm 1985; 42: 1965-9
74. Rivey MP, Peterson JP. Pharmacy-managed, weight-based heparin protocol. Am J Hosp Pharm 1993; 50: 279-84
75. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151: 333-7
76. Kershaw B, White RH, Mungall D, et al. Computer-assisted dosing of heparin: management with a pharmacy-based anticoagulation service. Arch Intern Med 1994; 154: 1005-11
77. Groce JB, Gal P, Douglas JB, et al. Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time. Clin Pharm 1987; 6: 216-22
78. Kandrotas RJ, Groce JB, Douglas JB, et al. Rapid determination of maintenance heparin infusion rates with the use of nonsteady state heparin concentrations [abstract]. Pharmacotherapy 1991; 11: 280
79. Joch LE, Lutomski DM, Williams DJ, et al. Accuracy of a first-order model for estimating initial heparin dosage. Clin Pharm 1993; 12: 597-601
80. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with nonbayesian methods. J Pharm Sci 1982; 71: 1344-8
81. Mungall D, Floyd R. Bayesian forecasting of APTT response to continuously infused heparin with and without warfarin administration. J Clin Pharmacol 1989; 29: 1043-7
82. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-9
83. Bain B, Forster T, Sleigh B. Heparin and the activated partial thromboplastin time: a difference between the in-vitro and in-vivo effects and implications for the therapeutic range. Am J Clin Pathol 1980; 74: 668-73
84. Zanke B, Shojania AM. Comparison of two APTT methods of monitoring heparin therapy: APTT ratio and heparin response of pooled normal plasma. Am J Clin Pathol 1990; 93: 684-9
85. Scialla SJ. Heparin monitoring by activated partial thromboplastin time: comparison of ex vivo measurement and in vitro standardization. Am J Clin Pathol 1985; 63: 16-23
86. Shojania AM, Tetreault J, Turnbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol 1988; 89: 19-23
87. Hauser VM, Rozek SE. Effect of warfarin on the activated partial thromboplastin time. Drug Intell Clin Pharm 1986; 20: 964-7
88. Fennerty AG. Guidelines to control heparin treatment. BMJ 1986; 292: 579-87
89. Feldig P. Adjusted-dose intravenous heparin treatment: evaluation of an automated and a nonautomated schedule. Thromb Res 1988; 51: 447-52
90. Rooke TW, Osmundson PJ. Heparin and the in-hospilal management of deep venous thrombosis: cost considerations. Mayo Clin Proc 1986; 61: 198-204
91. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17
92. Buckley MM, Sorkin EM. Enoxaparin: a review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992; 44: 465-97
93. Lensing AWA, Prins M, Davidson BL, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 1995; 155: 601-7
94. Lockner D. Low-molecular-weight-heparins for treatment of established venous thromboembolism. In: Bounameaux H, editor. Low-molecular-weight-heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker, Inc., 1993: 283-305
95. Stiekema JC, Van Griensven JM, Van Dinther TG, et al. A crossover comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. Br J Clin Pharmacol 1993; 36: 51-6
96. Barradell LB, Buckley MM. Nadroparin calcium: a review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992; 44: 858-88
97. Frampton JE, Faulds D. Parnaparin: a review of its pharmacology and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs 1994; 47: 652-76
98. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990; 40: 498-530
99. Harenberg J. Comparative human pharmacology of low molecular weight heparins. Semin Thromb Hemost 1989; 15: 414-23
100. Bara L, Samama MM. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand 1988; 543 Suppl.: 65-72
101. Bara L, Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand 1990; 156 Suppl. 556: 57-61
102. Frydman AM, Bara L, Le Roux Y, et al. The antithrombotic activity and pharmacokinetics of Enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80mg. J Clin Pharmacol 1988; 28: 609-18
103. Dawes J, Bara L, Billaud E, et al. Relationship between biological activity and concentration of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Hemostasis 1986; 16: 116-22
104. Agnelli G, Iorio A, Renga C, et al. Prolonged anti-thrombin activity of low molecular weight heparins: clinical implications for the treatment of thromboembolic diseases. Circulation 1995; 92: 2819-24
105. Lockner D, Bratt G, Törnebohm E, et al. Pharmacokinetics of intravenously and subcutaneously administered fragmin in healthy volunteers. Hemostasis 1987; 16 Suppl. 2: 8-10
106. Bratt G, Törnebohm E, Lockner D, et al. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemost 1985; 83: 206-11
107. Bratt G, Törnebohm E, Wildlund L, et al. Low molecular weight heparin (KABI 2165, FRAGMIN): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-20
108. Dettori AB, Tagliaferri A, Dall' Aglio E, et al. Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum). Int Angiol 1988; 7 Suppl. 3: 7-18
109. Follea G, Laville M, Pozet N, et al. Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure. Haemostasis 1986; 16: 147-51
110. Goudable C, That HT, Damani A, et al. Low molecular weight heparin half life is prolonged in hemodialysis patients. Thromb Res 1986; 43: 1-5
111. Simoneau G, Bergmann JF, Kher A, et al. Pharmacokinetics of a low molecular weight heparin in young and elderly subjects. Thromb Res 1992; 66: 603-7
112. Iorio A, Alatri A, Agnelli G. Non-anticoagulant actions of glycosaminoglycans: protein binding studies. In: Casu B, Harenberg J, editors. Nonanticoagulant actions of glycosaminoglycans. New York: Plenum Press, 1996: 101-12
113. Barzu T, Van Rijn JLMC, Petitou M, et al. Heparin degradation in the endothelial cells. Thromb Res 1987; 47: 601
114. van Rijn JLML, Trillou M, Mardiguian J, et al. Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics. Thromb Res 1987; 45: 211-22
115. Palm M, Mattson C. Pharmacokinetics of Fragmin: a comparative study in the rabbit of its high and low affinity forms for antithrombin. Thromb Res 1987; 48: 51-62
116. Forestier F, Sole Y, Aiach M, et al. Absence of transplacental passage of fragmin (Kabi) during the second and the third trimesters of pregnancy. Thromb Haemost 1992; 67: 180-1
117. Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 1984; 34: 557
118. Forestier F, Daffos F, Rainaut M, et al. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost 1987; 57: 234
119. Omri A, Delaloye JF, Andersen H, et al. Low molecular weight heparin NOVO (LNH-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 1989; 61: 55
120. Andersson L-O, Barrowcliffe TW, Holmer E, et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575
121. Jordan RE, Oosta GM, Gardner GM, et al. The kinetics of haemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980; 255: 10081
122. Hirsh J, Ofosu FA, Levine M. The development of low molecular weight heparins for clinical use. Leuven: International Society on Thrombosis and Haemostasis and Leuven University Press, 1987: 325
123. Buchanan MR, Boneu B, Ofosu F, et al. The relative importance of thrombin inhibition and factor Xa inhibition to antithrombotic effects of heparin. Blood 1985; 65: 198-201
124. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 1994; 24: 105-17
125. Bara L, Bloch MF, Zitoun D, et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-52
126. Bendetowicz AV, Beguin S, Caplain H, et al. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin: a three way cross over study in human volunteers. Thromb Haemost 1994; 71: 305-13
127. Iorio A, Alatri A, Mazzolai L, et al. Plasma thrombin neutralization assay: pharmacokinetic applications. Semin Thromb Hemost 1994; 20 (3): 266-73
128. Holmström M, Berglund M-C, Granqvist S, et al. Fragmin® once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thromb Res 1992; 67: 49-5
129. Lindmarker P, Holmström M, Granqvist S, et al. Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-90
130. Ozawa T, Mammen EF. LMW heparin (anti-Xa) assays for clinical monitoring and pharmacokinetic studies on the automated coagulation laboratory (ACL). Thromb Res 1992; 66: 287-98
131. Pattacini C, Manotti C, Fini M, et al. A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol). Thromb Haemost 1994; 71: 188-91
132. Breckenridge AM. Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol 1978; 15: 19-26
133. O'Reilly RA. Vitamin K and the oral anticoagulant drugs. Annu Rev Med 1926; 27: 245-61
134. Schoefield FW. A brief account of a disease of cattle simulating haemorrhagic septicemia due to feeding sweet clover. Can Vet Rec 1922; 3: 74
135. Link K. The discovery of dicumarol and its sequels. Circulation 1959; 19: 97-107
136. Mever O. Historical data regarding the experiences with coumarin anticoagulants at the University of Wisconsin Medical School. Circulation 1959; 19: 114-7
137. Porter RS, Sawyer WT. Warfarin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic monitoring. 3rd ed. Vancouver (WA): Applied Therapeutics, Inc., 1992: 1-46
138. Breckenridge AM, Orme M. Kinetics of warfarin absorption in man. Clin Pharmacol Ther 1984; 14: 955-61
139. Toon S, Trager WF. Pharmacokinetic implications of stereo-selective changes in plasma-protein binding: warfarin/sulfinpyrazone. J Pharm Sci 1984; 73: 1671-3
140. Lewis RJ. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974; 53: 1607-17
141. Banfield C, O'Reilly R, Chan E, et al. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br J Clin Pharmacol 1983; 16: 669-75
142. Okino K, Weibert RT. Warfarin-griseofulvin interaction. Drug Intell Clin Pharm 1986; 20: 291-3
143. Rowland M, Tozer TH. Clinical pharmacokinetics: concepts and applications. 2nd ed. Philadelphia: Lea & Febiger, 1989
144. Bell RG. Metabolism of vitamin K and prothrombin synthesis: anticoagulant and the vitamin K-epoxide cycle. Fed Proc 1978; 37: 2599-604
145. Richards RK. Influence of fever upon the action of 3-3′-methylene bis-(4-hydroxy-coumarin) (Dicumarol). Science 1943; 97: 313
146. Loeliger EA, van der Esch B, Mattern MJ, et al. The biological disappearance rate of prothrombin, factors VII, IX and X from plasma in hypothyroidism, hyperthyroidism, and during fever. Thromb Diath Haemorrh 1964; 10: 267-77
147. O'Reilly RA, Aggeler PM. Determinants of the response to oral anticoagulant drugs in man. Pharmacol Rev 1970; 22: 35-96
148. Breckenridge AM, Orme M, Wesseling H, et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974; 15: 424-30
149. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974; 16: 348-54
150. 12C-labelled racemates of warfarin in man [abstract]. Fed Proc 1978; 37: 545
151. Toon S, Low LK, Gibaldi M. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 1986; 39: 15-24
152. O'Reilly RA. Warfarin metabolism and drug-drug interactions. In: Wessler S, Becker CG, Nemerson Y, editors. The new dimensions of warfarin prophylaxis. New York: Plenum, 1986: 205-12
153. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976; 295: 354-7
154. O'Reilly RA. Stereoselective interaction of trimethoprimsulphamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980; 302: 33-5
155. O'Reilly RA, Trager WF, Motley CH, et al. Interaction of secobarbital with warfarin pseudoracemates. Clin Pharmacol Ther 1980; 28: 187-95
156. O'Reilly RA. Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med 1975; 83: 506-8
157. Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarin-carbamazepine interaction. South Med J 1990; 83: 981
158. Orme L, Lewis M, DeSwiet M. May mothers given warfarin breast-fed their infants? BMJ 1977; 1: 1564-5
159. McKenna R, Cale ER, Vasan V. Is warfarin sodium contraindicated in the lactating mother? J Pediatr 1983; 103: 325-7
160. Anand A. Oral anticoagulant therapy. Arch Intern Med 1993; 153: 1933
161. Mungall D, White R. Aging and warfarin therapy. Ann Intern Med 1992; 117: 878-9
162. Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992; 116: 901-4
163. Sheparid AM, Hewick DS, Moreland TA, et al. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977; 4: 315-20
164. Mungall DR, Ludden TM, Marshall J, et al. Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm 1985; 13: 213-26
165. Murray B, Coleman R, McWarters D, et al. Pharmacodynamics of warfarin at steady state. Ther Drug Monit 1987; 9: 1-5
166. Vigano S, Mannucci PM, Solinas S, et al. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol 1984; 57: 213-20
167. Broekmans AW. Development of skin necrosis during anticoagulant therapy. Thromb Haemost 1983; 49: 251
168. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-75
169. Weiss P. Decline of protein C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res 1987; 45: 783-90
170. McGehee WG. Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 1984; 101: 59-60
171. Horn J. Warfarin-induced skin necrosis: report of four cases. Am J Hosp Pharm 1981; 38: 1763-8
172. Jones R, Cunningham J. Warfarin skin necrosis. Br J Dermatol 1979; 100: 561-5
173. O'Reilly RA, Aggeler PM, Hoag MS, et al. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs: the first reported kindred. N Engl J Med 1964; 271: 809-15
174. Alving BM, Strickler MP, Knight RD, et al. Hereditary warfarin resistance. Arch Intern Med 1985; 145: 499-501
175. O'Reilly RA, Rytand DA. 'Resistance' to warfarin due to unrecognized vitamin K supplementation. N Engl J Med 1980; 303: 160-1
176. Suttie JW, Mummah-Schendel LL, Shah DV, et al. Vitamin K deficiency from dietary vitamin K restriction in humans. Am J Clin Nutr 1988; 47: 475-80
177. Lader E, Yang L, Clarke A. Warfarin dosage and vitamin K in osmolite. Ann Intern Med 1980; 93: 373-4
178. Levy G, Wingard L. Relationship between the kinetics of the anticoagulant effects of racemic warfarin and its individual enantiomers in man. Res Commun Chem Pathol Pharmacol 1974; 7: 359-65
179. Heimark LD, Wienkers L, Kunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992; 51: 398-407
180. Kates RE. Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther 1987; 42: 305-11
181. O'Reilly RA. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther 1987; 42: 290-4
182. Toon S, Hopkins KJ, Gargstang FM, et al. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 1987; 42: 33-41
183. Theofanous TG, Barile RG. Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing. J Pharm Sci 1973; 62: 261-6
184. Svec JM, Coleman RW, Mungall DR, et al. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation. Ther Drug Monit 1985; 7: 174-80
185. Murray B, McWaters D, Coleman R, et al. Pharmacodynamics of warfarin. Clin Pharmacol Ther 1985; 37: 215
186. Mungall DR. Predicting prothrombin time response to warfarin. Biotrack Information Bulletin. Sunnyvale: Biotrack Inc., 1984
187. Coleman R, Murray W, Hong R, et al. Predicting response to warfarin. Thromb Haemost 1985; 54: 79
188. Westboom TU, Marienrield RD. Prolonged hospitalization because of inappropriate delay of warfarin therapy in deep venous thrombosis. South Med J 1985; 78: 1164-7
189. Sawyer WT, Raasch RH. Effect of heparin on prothrombin time. Clin Pharm 1984; 3: 192-4
190. Routledge P. Predicting patient's warfarin requirements. Lancet 1977; II: 854-5
191. Miller D, Brown M. Predicting warfarin maintenance dosage based on initial response. Am J Hosp Pharm 1979; 36: 1351-5
192. McGhee J, Evans R, Wolfson PM, et al. Predictability of warfarin maintenance dosage based upon initial response. J Am Ostepath Assoc 1981; 80: 335-i9
193. Sawyer WT. Predictability of warfarin dose requirements: theoretical considerations. J Pharm Sci 1979; 68: 432-4
194. Carter B, Reinders T. Prediction of maintenance warfarin dosage from initial patient response. Drug Intell Clin Pharm 1983; 17: 23-6
195. Williams D, Karl R. A simple technique for predicting daily maintenance dose of warfarin. Am J Surg 1979; 137: 572-6
196. Sawyer WT. Predictability of warfarin maintenance dose: comparison of six methods. Clin Pharm 1985; 4: 440-6
197. O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs: initiation of warfarin therapy without a loading dose. Circulation 1968; 38: 169-77
198. Fennerty A. Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ 1984; 288: 1208-10
199. Cosh DG. Prospective evaluation of a flexible protocol for starting treatment with warfarin and predicting its maintenance dose. Aust NZ J Med 1989; 19: 191-7
200. Albrecht PH. Evaluation of a computer-assisted method for individualized anticoagulant therapy: retrospective and prospective studies using a pharmacodynamic model. Clin Pharmacol Ther 1982; 32: 129-36
201. Sawyer WT, Finn A. Digital computer-assisted warfarin therapy: comparison of two models. Comput Biomed Res 1979; 12: 221-31
202. Sheiner L. Computer-aided long-term anticoagulant therapy. Comput Biomed Res 1969; 2: 507-18
203. Weigman H, Vossepoel A. A computer program for long-term anticoagulation control. Comput Programs Biomed 1977; 7: 71-84
204. Rock WL. Evaluation of computer-assisted pharmacist consultation during initiation and stabilization of warfarin therapy [abstract]. 14th Annual ASHP Midyear Clinical Meeting; 1979: Las Vegas
205. Carter BL. Evaluation of three dosage-prediction methods for initial in-hospital stabilization of warfarin therapy. Clin Pharm 1987; 6: 37-45
206. Boyle DA. Evaluation of a Bayesian regression program for predicting warfarin response. Ther Drug Monit 1989; 11: 276-84
207. Lee C. Effect of using warfarin plasma concentrations in bayesian forecasting of prothrombin-time response. Clin Pharm 1987; 6: 406-12
208. Svec JM. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin time response to warfarin therapy: preliminary evaluation. Ther Drug Monit 1985; 7: 174-80
209. O' Quinn S, Sawyer WT. Comparison of two computer-assisted pharmacodynamic models for characterization of warfarin effect [dissertation]. Chapel Hill: School of Pharmacy, University of North Carolina, 1990
210. White RH, Hong R, Venook A. Initiation of warfarin therapy: comparison of physician dosing to computer-assisted dosing. J Gen Intern Med 1987; 2: 141-8
211. Bjornsson T. High-pressure liquid chromatographic analysis of drugs in biological fluids. I: warfarin. J Pharm Sci 1977; 66: 142-4
212. Loeliger EA. Reliability and clinical impact of the normalization of the prothrombin time in oral anticoagulant control. Thromb Haemost 1985; 53: 148-54
213. Koch-Weser J, Seliers E. Drug interactions with coumarin anticoagulants. N Engl J Med 1971; 285: 547-58
214. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs 1983; 25: 610-20
215. Williams J. Effect of concomitantly administered drugs on the control of long-term anticoagulant therapy. Q J Med 1976; 45: 63-73
216. MacLeod SM, Sellers EM. Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants. Drugs 1976; 11: 461-70
217. Koch-Weser J. Hemorrhagic reactions and drug interactions in 500 warfarin-treated patients. Clin Pharmacol Ther 1973; 14: 139-46
218. Schary WL, Lewis RJ, Rowland M. Warfarin-phenylbutazone interactions in man: a long term multiple-dose study. Res Commun Chem Pathol Pharmacol 1975; 10: 663-72
219. Cucinell SA, Conney AH, Sansur MS, et al. Lowering effect of phenobarbital on plasma levels of dicumarol and diphenylhydantoin. Clin Pharmacol Ther 1965; 6: 420-9
220. Stringer KA, Lindenfeld J. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992; 26: 1535-40
221. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91
222. Ekman S, Eriksson BI, Lindbratt S, et al. Recombinant hirudin, CGP 39393 15 mg (Revasc; Ciba), is the most effective and safe prophylaxis of thromboembolic complications in patients undergoing total hip replacement. Thromb Haemost 1995; 73: 1093
223. Eriksson BI, Kälebo P, Ekman S, et al. A dose-finding trial evaluating the efficacy and safety of three different doses of recombinant hirudin, CGP 39393, (Revasc; Ciba), in patients undergoing total hip replacement. Thromb Haemost 1995; 93: 1108
224. Eriksson BI, Kalebo P, Ekman S, et al. Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994; 72: 227-31
225. Schiele F, Vuillemenot A, Kramarz P, et al. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71: 558-62
226. Parent F, Bridey F, Dreyfus M, et al. Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost 1993; 70: 386-8
227. Moia M, Schiele F, Walker M, et al. Treatment of acute deep vein thrombosis (DVT) by subcutaneous r-hirudin (HBW 023): a multicentre study [abstract]. Thromb Haemost 1995; 73: 1456
228. Agnelli G, Pascucci C, Cosmi B, et al. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost 1990; 63: 204-7
229. Markwardt F, Nowak G, Sturzebecher J, et al. Clinico-pharmacological studies with recombinant hirudin. Thromb Res 1988; 52: 393-400
230. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23
231. Markwardt F, Nowak G, Sturzebecher J. Clinical pharmacology of recombinant hirudin. Haemostasia 1991; 21 Suppl. 1: 133-6
232. Walsmann P, Baiser B. Biochemical and pharmacological properties of recombinant hirudin. Drugs Today 1989; 25: 473-85
233. Nowak G, Bucha E, Goock T, et al. Pharmacology of r-hirudin in renal impairment. Thromb Res 1992; 66: 707-15
234. Bichler J, Siebeck M, Fichti B, et al. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man. Haemostasis 1991; 21 Suppl.: 137-41
235. Meyer BH, Luus HG, Muller FO, et al. The pharmacology of recombinant hirudin: a new anticoagulant. S Afr Med J 1990; 78: 268-70
236. Markwardt F, Nowak G, Sturzebecher J, et al. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemost 1984; 52: 160-3
237. Marbet GA, Verstraete M, Kienast J, et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol 1993; 22: 364-72
238. Richter M, Walsmann P, Markwardt F. Plasma level of dextranhirudin. Pharmazie 1989; 44: 73-4
239. Markwardt F, Richter M, Walsmann P, et al. Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behaviour. Biomed Biochim Acta 1990; 49: 1103-8
240. Ito R, Phaneuaf MD, Logerfo FW. Thrombin inhibition by covalently bound hirudin. Blood Coag Fibrinol 1991; 2: 77-81
241. Rübsamen K, Eschenfelder V. Reocclusion after thrombolysis: a problem solved by hirudin. Blood Coag Fibrinol 1991; 2: 97-100
242. Verstraete M, Nurmohamed M, Kienast J, European Hirudin in Thrombosis Group, et al. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coll Cardiol 1993; 22: 1080-8
243. Goldhaber SZ, Buring JE, Lipnick RJ, et al. Pooled analysis of randomized trials of streptokinase and heparin in phlebographically documented acute deep vein thrombosis. Am J Med 1984; 76: 393-7
244. Goldhaber SZ, Meyerovitz MF, Green D. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990; 88: 235-40
245. Goldhaber SZ, Kessler CM, Heit J. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; II: 293-8
246. Marder VJ, Bell WR. Fibrinolytic therapy. In: Colman RW, Hirsh J, Marder VJ, et al., editors. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott, 1987: 1395-437
247. Rogers LQ, Lutcher CL. Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature. Am J Med 1990; 88: 389-95
248. Turpie AGG, Levine MN, Hirsh J, et al. Tissue plasminogen activator (rt-PA) versus heparin in deep vein thrombosis: results of a randomized trial. Chest 1990; 97 Suppl.: 172S-5S
249. Verhaeghe R, Besse P, Bounameaux H, et al. Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis. Thromb Res 1989; 55: 5-11
250. Marder VJ, Brenner B, Totterman S, et al. Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med 1992; 119: 485-95
251. Agnelli G, Parise P. Bolus thrombolysis in venous thromboembolism. Chest 1992; 101 Suppl.: 172S-82S
252. Weitz JI, Leslie B, Ginsberg J. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis. J Clin Invest 1991; 87: 1-10
253. Agnelli G, Buchanan MR, Fernandez F, et al. Sustained thrombolysis with recombinant tissue type plasminogen activator in rabbits. Blood 1985; 66: 399-401
254. Agnelli G. Rationale for bolus t-PA therapy to improve efficacy and safety. Chest 1990; 97 Suppl.: 161S-7S
255. Agnelli G, Buchanan MR, Fernandez F, et al. A comparison of the thrombolytic and haemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. Circulation 1985; 72: 178-82
256. Agnelli G, Buchanan MR, Fernandez F, et al. The thrombolytic and haemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. Thromb Res 1985; 40: 769-77
257. Clozel JP, Tschopp T, Luedin E, et al. Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model. Circulation 1989; 79: 125-33
258. Schiffman F, Ducas J, Hollett P, et al. Treatment of canine emholic pulmonary hypertension with recombinant tissue plasminogen activator: efficacy of dosing regimens. Circulation 1988; 78: 214-20
259. Goldhaber S, Agnelli G, Levine M, et al. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary thrombolysis: an International Multicenter Randomized Trial. Chest 1994; 106: 718-24
260. Levine M, Hirsh J, Weitz J, et al. A randomized trial of single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1473-9
261. Martin M, Fiebach BJO. Short-term ultrahigh streptokinase treatment of chronic arterial occlusions and acute deep vein thromboses. Semin Thromb Haemost 1991; 17: 21-38
262. Sasahara AA, Henkin J, Janicki RS. Urokinase versus tissue plasminogen activator in pulmonary embolism. Lancet 1988; II: 691
263. Levine MN, Weitz J, Turpie AGG, et al. A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease. Chest 1990; 97 Suppl.: 168S-71S
264. O'Meara III JJ, McNutt RA, Evans AT, et al. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep vein thrombosis. N Engl J Med 1994; 330: 1864-9
265. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1990; 78: 268-70